Production (Stage)
Yubo International Biotech Limited
YBGJ
$0.0612
$0.015233.04%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | -- | -- | 3.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | -- | -- | 3.50K |
| Cost of Revenue | -- | -4.30K | 88.30K | 127.90K | 800.00 |
| Gross Profit | -- | 4.30K | -88.30K | -127.90K | 2.70K |
| SG&A Expenses | 380.40K | 284.40K | 395.80K | 287.10K | 280.20K |
| Depreciation & Amortization | 44.60K | 42.40K | 49.60K | 44.80K | 46.50K |
| Other Operating Expenses | 42.30K | 30.50K | 87.40K | 138.50K | 85.30K |
| Total Operating Expenses | 467.30K | 353.00K | 621.10K | 598.30K | 412.90K |
| Operating Income | -467.30K | -353.00K | -621.10K | -598.30K | -409.40K |
| Income Before Tax | -467.30K | -352.90K | -621.10K | -598.30K | -409.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -467.30K | -352.90K | -621.10K | -598.30K | -409.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 31.70K | 63.20K | 40.20K | 70.80K | 32.20K |
| Net Income | -435.60K | -289.70K | -580.80K | -527.50K | -377.30K |
| EBIT | -467.30K | -353.00K | -621.10K | -598.30K | -409.40K |
| EBITDA | -422.70K | -310.60K | -572.70K | -552.30K | -362.90K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 |
| Average Basic Shares Outstanding | 119.82M | 119.82M | 119.82M | 119.82M | 11.98M |
| Average Diluted Shares Outstanding | 119.82M | 119.82M | 119.82M | 119.82M | 11.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |